1-4 of 4
Eyal C. Attar, M.D.
Close
Sort by
Journal Articles

Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502

Eyal C Attar, M.D., Kathleen A. Donohue, M.A., Philip C. Amrein, MD, Martha Wadleigh, MD, Daniel J DeAngelo, MD, PhD, Jonathan E Kolitz, MD, Bayard L. Powell, MD, Peter M Voorhees, M.D., Eunice S. Wang, MD, William Blum, MD, Allison Booth, Richard M Stone, M.D., Barry K Moser, Ph.D., Richard Larson, M.D.
Journal: Blood
Blood (2010) 116 (21): 331.
https://doi.org/10.1182/blood.V116.21.331.331
Published: 2010
Journal Articles

A Phase II Study of Dasatinib in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL/SLL).

Philip C. Amrein, MD, Eyal C. Attar, M.D., Tak Takvorian, M.D., Ephraim P. Hochberg, M.D., Karen Ballen, M.D., David Zahrieh, M.S., Jennifer R. Brown, M.D.
Journal: Blood
Blood (2007) 110 (11): 3126.
https://doi.org/10.1182/blood.V110.11.3126.3126
Published: 2007
Journal Articles

In Vitro Studies of Bortezomib with Daunorubicin and Cytarabine:Sequence of Administration Affects Leukemia Cell Chemosensitivity.

Eyal C. Attar, M.D., Emily Learner, Philip C. Amrein, M.D.
Journal: Blood
Blood (2004) 104 (11): 4464.
https://doi.org/10.1182/blood.V104.11.4464.4464
Published: 2004
Journal Articles

Phase I Dose Escalating Trial of Bortezomib (Velcade®) in Combination with Idarubicin and Cytarabine in Patients with Acute Myeloid Leukemia.

Eyal C. Attar, M.D., Daniel J. DeAngelo, M.D., Ph.D., Karen K. Ballen, M.D., Emily Learner, Elizabeth G. Trehu, M.D., David P. Schenkein, M.D., James D. Levine, M.D., Richard M. Stone, M.D., Philip C. Amrein, M.D.
Journal: Blood
Blood (2004) 104 (11): 1799.
https://doi.org/10.1182/blood.V104.11.1799.1799
Published: 2004